NEW YORK, May 12, 2026
Neurogene presented new data at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting supporting the therapeutic rationale for using intracerebroventricular (ICV) administration in central nervous system-targeted gene therapy programs, particularly its lead NGN-401 gene therapy for Rett syndrome. The company highlighted preclinical and clinical findings demonstrating that ICV administration enables broader biodistribution of gene therapy across critical brain regions involved in neurological disease compared with traditional intrathecal-lumbar delivery methods. Neurogene stated that the latest findings reinforce the scientific foundation supporting the ongoing Embolden™ registrational trial of NGN-401, which is currently one of the most advanced gene therapy programs in development for Rett syndrome. The ASGCT presentations also strengthen growing industry interest in precision CNS-targeted gene therapies designed to improve neurological function through optimized delivery strategies and tightly controlled transgene expression.
Neurogene Demonstrates Advantages of ICV Gene Therapy Delivery
According to Neurogene, the ASGCT presentation titled “Gene Therapy Targeting CNS Diseases: ICV Administration as a Growing Standard for Delivery” highlighted the growing role of ICV delivery as a routine neurosurgical approach for central nervous system gene therapies. The company reported that preclinical studies comparing ICV administration with intrathecal-lumbar delivery showed significantly broader biodistribution of NGN-401 to key brain regions associated with Rett syndrome pathology, including the motor cortex, frontal cortex, cerebellum, and broader CNS structures. Researchers emphasized that effective delivery to widespread regions of the brain remains one of the most critical challenges in developing durable gene therapies for severe neurological diseases.
Neurogene also noted that the ICV procedure itself is already widely utilized by pediatric and adult neurosurgeons across multiple therapeutic areas and typically requires approximately 10 minutes for administration. The company stated that available clinical evidence suggests safety outcomes in CNS gene therapy are driven primarily by vector biology, transgene expression levels, and viral dose, rather than the delivery procedure itself. These findings are particularly important for NGN-401 because the therapy uses a one-time AAV9-based gene therapy platform designed to deliver the full-length MECP2 gene, the underlying genetic driver of Rett syndrome. Neurogene believes that achieving broader brain biodistribution may improve the likelihood of durable multidomain neurological benefits in patients receiving treatment.
The company also highlighted encouraging interim clinical findings from its ongoing Phase 1/2 trial of NGN-401. According to Neurogene, treated patients demonstrated durable improvements across multiple functional domains including communication, fine motor skills, gross motor function, and developmental milestones. Interim analyses previously reported that approximately 88% of participants showed improvement on Clinical Global Impression scales, while patients collectively achieved dozens of new developmental milestones following treatment. Neurogene additionally stated that NGN-401 at the 1E15 vg dose has remained generally well tolerated with no reported cases of hemophagocytic lymphohistiocytosis (HLH) observed in either the Phase 1/2 study or the Embolden registrational trial as of May 2026.
Advertisement
NGN-401 Advances Toward Potential Registrational Milestones
Neurogene confirmed that approximately 90% of participants have now been dosed in the ongoing Embolden registrational clinical trial, with full enrollment and dosing expected to be completed during the second quarter of 2026. The company plans to present updated interim safety and efficacy data later this year, including at least 12 months of follow-up for all Phase 1/2 participants. Neurogene is also preparing for future commercial manufacturing activities through planned Process Performance Qualification (PPQ) campaigns expected to begin in mid-2026.
NGN-401 remains differentiated within the Rett syndrome treatment landscape because it combines delivery of the full-length human MECP2 gene with Neurogene’s proprietary EXACT™ transgene regulation technology, designed to tightly control protein expression on a cell-by-cell basis. Precise regulation of MECP2 expression is considered critically important because both insufficient and excessive protein expression may lead to neurological complications. Neurogene believes its EXACT platform may help address one of the major historical limitations associated with MECP2 gene replacement strategies.
Neurogene Strengthens Position in CNS Genetic Medicine
The ASGCT 2026 presentations reflect Neurogene’s broader strategy to position itself as a leader in precision neurological gene therapy development. Rett syndrome remains a devastating rare neurodevelopmental disorder primarily affecting girls and is characterized by severe cognitive impairment, loss of motor skills, seizures, communication difficulties, and autonomic dysfunction. Current treatment options remain extremely limited, increasing industry interest in disease-modifying gene therapies capable of targeting the underlying genetic cause of disease.
The broader CNS gene therapy market has experienced rapid growth as biotechnology companies pursue optimized delivery technologies, advanced vector engineering, and regulated gene expression systems capable of improving efficacy and safety in neurological disorders. Neurogene executives stated that the latest ASGCT findings reinforce the company’s biology-first approach focused on maximizing therapeutic delivery to affected brain regions while maintaining controlled transgene activity. With multiple gene therapy programs across rare neurological diseases continuing to advance clinically, Neurogene aims to establish NGN-401 as a potentially best-in-class one-time therapy for Rett syndrome while expanding the broader application of its CNS-targeted gene regulation technologies.
Source: Neurogene press release
